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Airway inflammation is considered to be the primary component contributing to the heterogeneity and severity of
airway disorders. Therapeutic efficacies of diverse novel biologics targeting the inflammatory pathways are under
investigation. One such target is IL-5, a type-1 cytokine that is central to the initiation and sustenance of eosinophilic
airway inflammation. Over the past decade, anti-IL5 molecules have been documented to have mixed therapeutic
benefits in asthmatics. Post hoc analyses of the trials reiterate the importance of identifying the IL-5-responsive patient
endotypes. In fact, the currently available anti-IL5 treatments are being considered beyond asthma management;
especially in clinical complications with an underlying eosinophilic pathobiology such as hypereosinophilic syndrome
(HES) and eosinophilic granulomatosis and polyangitis (EGPA). In addition, closer analyses of the available data indicate
alternative mechanisms of tissue eosinophilia that remain uncurbed with the current dosage and delivery platform of
the anti-IL5 molecules.
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Mepolizumab, Reslizumab, BenralizumabIntroduction
The past ten years have witnessed the development and
evaluation of a number of biologics that target the Th2
cytokines involved in asthma pathophysiology, particularly
those that are associated with eosinophils in the airway.
Eosinophils play a key role in the pathobiology of several
airway disorders presenting with chronic inflammatory
pathology such as asthma [1,2], chronic obstructive pul-
monary disorder (COPD) [3], eosinophilic granulamatosis
and polyangitis (EGPA) [4], and hypereosinophilic syn-
drome (HES) [5]. Targeting Interleukin-5 (IL-5) in asthma,
the central protagonist in eosinophilia (discussed in details
later), was a logical derivative post promising results in ani-
mal models [6,7] and initial screenings in patients [8,9]. De-
liberation arises from the mixed response of anti-IL-5 trials
conducted in different asthmatic populations that docu-
ment a healthy reduction in circulating eosinophils, but
without much significant improvement in other clinical in-
dices of disease severity (extensively reviewed in [10-12]).
Again in a recent review, anti-IL-5 therapy has been conjec-
tured to be effective in long-term management of HES* Correspondence: parames@mcmaster.ca
St Joseph’s Healthcare & Department of Medicine, Firestone Institute for
Respiratory Health, McMaster University, 50 Charlton Avenue East, Hamilton,
Ontario L8N 4A6, Canada
© 2014 Mukherjee et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.patients [5]. The current review will critically evaluate the
documented outcomes of the conducted clinical trials to
date and subsequently assess the therapeutic implications
of anti-IL-5 therapy in treating airway disorders with an ab-
errant eosinophilic pathobiology.Eosinophil biology and the role of IL-5
A robust literature now support eosinophils to be pleio-
tropic, multifunctional leukocytes that facilitate the ‘innate’
response against extraneous agents in the airway, modulate
the downstream ‘adaptive’ immunity cascade, maintain local
immunity/inflammation and as the end-stage effector cells
that can cause tissue damage via release of granule proteins,
reactive oxygen species and cysteinyl leukotrienes (reviewed
in [2,13]). In eosinophil biology (refer to Figure 1), IL-5 plays
a central role in the production, mobilization, activation,
recruitment, proliferation, survival and suppression of apop-
tosis in eosinophils at the site of inflammation (reviewed
in, [2,6,12,13]), illustrated in a schematic diagram (Figure 1).
In 1996, a study reported that ‘IL-5 deficient’ mice
failed to develop the characteristic eosinophilia and air-
way hyper-reactivity after ovalbumin-sensitization [7].
Soon after, 8 asthmatic patients demonstrated increase
in airway eosinophil counts and methcholine PC20 (a
provocative concentration of methcholine required totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 A schematic representation of eosinophilia in the airways. The figure portrays (A) the complex eosinophil biology: Maturation:
CD34+ myeloid progenitor cells (bone-marrow) differentiate into the IL5α+ CCR3+ eosinophil-committed progenitor cells under the influence of
the different transcription factors like GATA2 and C/EBPα. IL-5, IL-3 and GM-CSF stimulate their further maturation into eosinophils. Migration: release
into the circulation is coordinated synergistically by IL-5 and eotaxin. Transmigration: under the influence of IL-5 and eotaxin, the eosinophils ‘seep’
out through the endothelium. Recruitment: Eosinophil trafficking into the site of inflammation is selectively regulated by IL-5, eotaxin and
CCL5, in addition to a multitude of cytokines. Activation: IL-5 binds to IL-5Rα and activates eosinophils to release a multitude of cytokines,
eosinophilic granular proteins, cysteinyl leukotrienes, that lead to tissue damage and further aggravates the inflammatory process. Survival and
stabilisation: IL-5 released from different sources and products from mast cell (MC) degranulation suppresses apoptosis and allows survival of
eosinophils in the submucosa. (B) Different sources of IL-5 (in red) and sustenance of eosinophilia: (i) the canonical TH2 pathway initiated by
dendritic cell (DC) activation releases IL-5. (ii) MC activation is another source of IL-5 that can be triggered by IgE binding to the FCεRI receptor or by
epithelial-derived Type 2 alarmins like TSLP and IL33; or via TH9 pathway (iii) Type-2 alarmins (IL-33, IL-25, TSLP) can activate the lineage negative ID2
+
lymphoid cells resident in the tissue to differentiate into lineage negative ILC2s that can release IL-5 and IL-13, and drive eosinophilic inflammation
(iv) IL-13 and IL-4 can recruit CD34+ progenitors cells from bone marrow into the lung tissue where it can differentiate into eosinophils in presence
of IL-5. N.B. Diagram is not up to scale. Mechanisms relevant to only eosinophilic inflammation has been included.
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1 second, FEV1) when subjected to inhaled recombinant
IL-5 [9]. Moreover, restraining sources of eosinophil re-
cruitment and/or eosinophil-deficient animal modelswere observed to be healthy without any characteristic
abnormalities [14]. As a logical derivative from the
existing experimental and clinical evidences, several
monoclonal antibodies (mAbs) were engineered to
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ceptor alpha (IL5Rα) and are now in different phases of
development [10,12,15].
A comparative analysis of the Anti-IL-5 trials: asthma
As early as 1990, Bousquet et al., [8], correlated eosinophilia
with asthma severity and demonstrated eosinophilic cation
proteins (ECP) were associated with epithelial damage in 44
patients with asthma. A direct but modest correlation has
been established between asthma severity, frequent exacer-
bations and the intensity of eosinophilia. Thereby, a sub-set
of patients are being identified who suffer from ‘severe re-
fractory asthma’, consequently accounting for a high socio-
economic burden and are considered to most benefit from
an eosinophil-targeted therapy [1,10].
The last 15 years have documented several clinical trials
that evaluate the therapeutic relevance of anti-IL-5 biologics
in asthma treatment and symptom management (refer to
Table 1). As evident from the outcome summary tabulated
in Table 1, Mepolizumab, a humanized mAb (IgG1) with a
high affinity for binding free IL-5 (which further prevents
its binding to the receptor, IL5Rα), is found to be effective
in depleting eosinophil numbers in blood and the airways.
On the contrary, studies in mild-moderate asthmatics
documented Mepolizumab to be ineffective in improving
end-point clinical symptoms (refer to Table 1, [16,19,20]),
therefore raising concern over the efficacy of IL-5 as a
therapeutic intervention in asthma. However, by selecting
patients with persistent blood ( >0.3 × 109/L) and sputum
eosinophils (≥3%) coupled with frequent history of exacer-
bations, two independent relatively small studies in 2009
documented a significant decrease in the exacerbation fre-
quencies (P ≤ 0.02 vs. placebo, both studies) and asthma
control questionnaire (ACQ) scores (P ≤ 0.02, vs. placebo,
both studies), with 750 mg infusions of Mepolizumab
[21,22]; in addition to a prednisone-sparing effect [21].
Similar reduction in exacerbation frequencies with corre-
sponding decrease in peripheral blood eosinophils was
reflected in a large, double-blinded, placebo-controlled,
multi-centered study conducted in 2011 [23]. Based on the
dose–response observations from the DREAM study [23],
75 mg intravenous and 100 mg subcutaneous doses were
investigated in a recent Phase III trial, where significant re-
ductions in exacerbation rates by 47% and 53% respectively
(P< 0.001, vs. placebo) along with depletion of blood eosino-
phils were recorded [28]. The 100 mg subcutaneous dose
was reported in a parallel Phase III study to have a
corticosteroid-sparing effect in a similar target population,
with median percentage reduction of 50% in treatment
group, along with 32% relative reduction in annual exacer-
bation rate (p= 0.04 vs placebo) [29]; a reduction though
statistically significant, is less pronounced than that ob-
served in the earlier study with higher dose and intravenous
route of drug delivery [21,32]. The optimum dose, routeand duration of therapy and persistence of beneficial
effects for prednisone-dependent patients remain to be
established.
Another anti-IL5 mAb (IgG4/k) Reslizumab, showed
similar reduction in sputum eosinophils, significant im-
provement in lung function (P= 0.002, vs. placebo) and a
trend towards improved asthma scores (P= 0.054, vs. pla-
cebo) in patients diagnosed with severe refractory eosino-
philic asthma (see Table 1). Additionally, the authors
observed the improvement in ACQ scores were most pro-
nounced in patients with nasal polyps (P= 0.012, vs. pla-
cebo), [24] which reflected the observations of Gevaert
et al., in 2003 [33]. There are recent reports of Phase III tri-
als that demonstrate significant improvement in ACQ
scores and FEV1 (p<0.05, vs. placebo) in moderate to severe
asthmatics treated with 3.0 mg/kg of intravenous Reslizu-
mab; charting a larger improvement in asthma control for
subjects with baseline eosinophils ≥400 cells/μl [30,31].
IL5Rα expressed by both mature eosinophils and eosi
nophil-lineage progenitor cells [2], is targeted by Benrali-
zumab (MEDI-563), a humanized, afucosylated mAb.
Being afucosylated, this drug induces apoptosis in its tar-
get cells via enhanced antibody-mediated cellular toxicity
(ADCC), and is considered to have an increased efficiency
of eosinophil depletion comparative to the other anti-IL5
biologics [34]. The initial safety trial conducted by Busse
et al., in 2010, documented no adverse events [25] and a
further study by the same group showed 100% reduction
of peripheral circulating eosinophils (Table 1) [26]. More
recently, 100 mg subcutaneous Benralizumab exhibited
significant improvement in annual exacerbation rates,
lung function and asthma score, with greater benefits seen
in patients with blood eosinophil levels ≥ 400 cells/μl
[27]. Currently, there are three clinical trials registered
on http://clinicaltrials.gov (NCT01914757, NCT02075255,
NCT01928771, last accessed 17/09/2014), where the drug
is being assessed as an adjunct therapy for ‘uncontrolled’
asthma.Further assessment of anti-IL5 Trials: clinical insights
The mixed outcomes from anti-IL-5 clinical trials highlight
the need for careful endotyping of patients, since the ther-
apy is deemed effective on those patients whose asthma is
dependent on the eosinophilic inflammatory pathway [1].
The potential ‘responders’ to IL-5 therapy are patients who
present with eosinophilia (blood >0.3 × 109/L, >3% spu-
tum), are generally steroid-responsive, and suffer from fre-
quent exacerbations. As evident from the DREAM study
[23], the atopic status is inadequate for segregating ‘re-
sponders’ from the ‘non-responders’, since approximately
50% of the patients who responded to Mepolizumab had
negative radioallergosorbent test to the four most common
allergens. In addition, sub-sets of patients that are aspirin-
Table 1 A comparative study of Anti-IL5 trials in Asthma
First author [ref]
year/ Drug
Disease (severity) Study design Dosage/ delivery Inclusion criteria:
Baseline eosinophil
count
Comments on eosinophilia Outcome summary
Leckie [16] 2000 Mild atopic asthmatic n= 24
mc, db, pc
Single dose i.v., 2.5,
10 mg/kg
• Not an inclusion
criteria
• Day 29, post-allergen 10 mg/kg d age,
blood eos 0.04 × 109/L compare o 0.25 ×
109/L placebo (P< 0.0001)
• No significant effect on AHR
Mepolizumab FEV1≥ 70%,
predicted
Baseline values: • No significant effect on late
asthmatic response to allergen
challenge•Sputum eos (%
mean) > 11% in all
groups
• Day 29, post- allergen,10 mg/kg sage:
0.7% sputum eos compared to 1 %
placebo ( p= 0.005)
• Blood eos (counts ×
109/L) > 0.2 in all
groups




Three monthly doses, i.v. No Baseline count/
median n/a
• Decrease in blood eos (median v es from
300 to 45 per mL, P< 0.05 vs. pla o)
• No asthma end-points were assessed
Mepolizumab FEV1 > 50-80%,
predicted
250/750 mg • T-cell sub-sets and T-cell cytokine
levels not altered
• Decreased levels of serum ECP (m ian
values from 15 to 5 mg.L−1, P< 0 vs.
placebo)
• No sputum data
Kips [18] 2003 Moderate-severe





(0.03, 0.1 , 0.3, 1 mg/
kg) i.v
• Not included in the
inclusion criteria
• Dose dependently reduced circu ng eos • Significant increase in FEV1 post
24 hours from dose range≥ 0.3 mg/
kg (p= 0.019)
Reslizumab Baseline value: • Significant dose reduction with 1 g/kg for
30 days post dosing ( p=0.05)
• blood eos (counts ×
109/L):
• No significant changes in other
clinical indices
Placebo:0.45 ± 0.16 • No significant trend in changes o putum
eos were observed between gro due to
the wide variability in baseline co ts
between the groups
0.3 mg/kg : 0.28 ± 0.04
1.0 mg/kg : 0.25 ± 0.04
• Sputum eos (% mean)
Placebo:22.9 ± 12.5
0.3 mg/kg : 2.6 ± 0.44
1.0 mg/kg : 5.5 ± 3.92
Flood-page [19]
2003
Mild atopic asthma n= 24
db, pc, parallel-
group,
3 i.v. doses of 750 mg • Not included in the
inclusion criteria
• Blood eos: significant reduction i k 4 and
10 (P<0.02, vs. placebo)






Baseline value: • No change in clinical parameters,
FEV1, AHR
• Blood eos (mean ×
109/L):
• Bone marrow: 70% reduction in m ture eos
(P= 0.017)
Group: 0.27
Placebo: 0.4 • BAL fluid eos: median reduction 79% from










































3 i.v. doses of • Not included in the
inclusion criteria
• Blood eos: Sustained significant 8
reduction for both doses ( p< 0.0 vs.
placebo)







• Baseline blood eos
for all group
showed median
values ≥ 0.3 × 109/L
• Sputum eos significant reduction m
baseline (P=0.006, 250 mg, P= 0. , 750 mg)
• Trend for a reduction in exacerbation
rate, ns
• Decrease in summary symptom
score vs. placebo for 750 mg at wk
12 (P= 0.032)
8- wk follow up
Nair [21] 2009 Severe persistent
asthma with
Eosinophilia





• Significant reduction in blood eo fter 1st
dose (49.5/μl), last dose (64.5/μl) d follow
up (76.3/μ) (P< 0.05) vs. placebo,
significant reduction from baselin
• Significant reduction in asthma
exacerbations with drug (1)
compared to placebo (12 in 10
patients), P< 0.01
Mepolizumab db, pc, pilot study
FEV1%,predicted
value (median ± SD):






• Blood eos; • 83.8% reduction in prednisone dose
vs. placebo (P< 0.04)
Drug: 664 ± 492.5/μl;
placebo:352 ± 253.7/μl
• Significant reduction in sputum after 1st
dose (0%), last dose (1.3%) and f w-up
(0.3%) (P< 0.05) vs. placebo, no s ificant
reduction from baseline
• FEV1 - significant improvement vs.
placebo, P< 0.05
• Sputum eos:
Drug group: 16.6% • ACQ: significant improvement from
baseline P= 0.01, vs. placebo
Placebo: 4%






12 doses of 750 mg
i.v. per month
• Inclusion criteria -
Sputum eos > 3%
• Blood eos: reduced by a factor o .6 from
baseline in drug group, compare o 1.1 in
placebo (P<0.001)
• Reduction in number of exacerbation
over the course of 50 wks (P= 0.02)
Mepolizumab Baseline:
• Blood eos (x 109/L); • AQLQ score increase with drug
(P= 0.02, vs. placebo)
Drug:0.32 ± 0.38
placebo: 0.35 ± 0.30
• Sputum eos: reduced by a factor 7.1 from
baseline in drug group, compare o 1.9 in
placebo (P=0.002)
• Sputum eos: • No significant difference in group in
AHR, FEV1, ACQDrug: 6.84 ± 0.64%
Placebo:5.46 ± 0.75%
Pavord [23] 2012 Severe refractory
asthma with ≥ 2
exacerbations in past
year
n= 621 3 doses s.c., at 4 wks • Yes. Inclusion
criteria - Sputum
eos > 3%
• Blood eos (x109/L): at 52 wk, vs. ebo • Exacerbation rates at all doses were
39-52% less than those in the
placebo group (P< 0.05 vs. placebo)Mepolizumab db, pc, parallel
study, mc
75/250/750 mg 75 mg: 0.22< 0.0001, 250 mg: 0.14 0.0001
(DREAM) 52 wk Blood eos≥ 0.3 x109/L 750 mg:0.12 p< 0.0001
Baseline: • Sputum eos (ratio): at 52 wk • No changes in FEV1, ACQ, AQLQ
• Blood eos (x 109/L); 75 mg : 0.68, ns • Lowest dose of 75 mg was near to
the top of the dose response curve
w.r.t reduction of blood eosinophils>0.2 , for all groups 250 mg: 0.35, ns
• Sputum eos: 750 mg :0.12, p= 0.0082




































Table 1 A comparative study of Anti-IL5 trials in Asthma (Continued)
Castro [24] 2011 Poorly controlled
asthma, on high dose
ICS
n= 106 3.0 mg/kg sc, at
baselineand at Weeks




• Significant reduction in blo ophils
(P< 0.0001, vs. placebo)
• Trend in reduction of asthma
exacerbations in drug group
(p= 0.083, ns)Reslizumab db, pc, parallel
study,
Baseline: • 95.4% reduction in sputum pared to
placebo, 38.7% (p= 0.0068)
• ACQ trend in favour of drug group
(p=0.054)
• Blood eos , median
(x 103/μL);
• Significant improvement in ACQ
score in patients with nasal polyps
(p= 0.012)
Drug: 0.5
Placebo: 0.5 • Significant reduction in FEV1 in drug
group (p=0.002, vs. placebo)
• Sputum eos (%):
Drug: 10.7
Placebo: 8.5





kg, over 3 –
30 minutes)
No. this was a safety
study.
• Significant decrease in eos
dependent fashion from ba 0.01 ±
0.0 × 103/μL, 24 hours post





Baseline: • No adverse reactions were noted.
• Blood eos:
Mean ± SD, 0.27 ±
0.2 × 103/μL
• 94% patients on doses ≥03 howed
0–0.1 × 103/μL blood eos.
• ECP levels (mean)
21.4 ± 17.2 μg/L • ECP levels were reduced fr ine to
10.3 ± 7.0 μg/L, 24 hrs post
Laviolette [26]
2013
Eosinophilic asthma n= 27
mc, db, pc
• Cohort 1 – (i.v)
1 mg/kg single dose
• Sputum eosinophil
counts of ≥2.5%
• Significant reduction in spu inophils,
airway eosinophil counts a
reduction in bone marrow pheral
blood




Baseline:• Cohort II-100 mg,
200 mg, combined 3
monthly (s.c). • Sputum eos (mean%) • Airway mucosal/submucos ean
reduction vs. placebo:
• Cohort 1:
Placebo : 13.9 Cohort I : (i.v.) 61.9% (ns)
Drug: 6.6 Cohort II, combined (sc): 83.1 .0023)
• Cohort II: • Induced sputum eos (mean
Placebo: 34.1 Cohort I: 4.5%, day 21 comp 0.8%
placebo
100 mg: 10.5
200 mg: 4.9 Cohort II: (combined) 0.6% a




































Table 1 A comparative study of Anti-IL5 trials in Asthma (Continued)
Castro [27] 2014 Uncontrolled asthma
ACQ-6 score≥ 1.5
n= 609 • 2 mg, 20 mg,






eos ≥2%, FeNO >
50 ppb
• All doses reduced blood eos<50 cells/μl after
the first dosage
• Significant improvement in FEV1 and




• In eosinophilic group, 100 mg sc improved
annual exacerbation rate by 41% (p= 0.096)
vs. placebo, deemed significant; ns in non-
eosinophilic group,
• High incidence of adverse reactions
in treatment arm
Phase IIb • 100 mg sc for non-
eosinophilic (n= 282)
Db, pc, dose-
ranging study • 7 doses every
4 weeks
• Subgroup analysis showed greater
improvement with increased baseline blood
eos (100 mg sc reduced exacerbations by
70% in patients ≥ 400 cells/μl, p= 0.002)
Ortega [28] 2014 Severe asthma n= 576 • Cohort 1 – 75 mg i.v.
(n= 191)
• Blood eos 150/μl at
screening or 300/μl
in previous year
• Reduction in eos by week 4 mainted
through the entire study
• Rate of exacerbations reduced by
47% and 53% in s.c and i.v. groups
respectively (p< 0.001, vs. placebo)Mepolizumab Recurrent
exacerbations, with
≥2 in previous year
mc, db, pc
Phase III • Cohort 2 –
100 mg s.c. (n= 194)
• No sputum eos
were accounted
• 83% reduction in i.v. group
ICS dose ≥880 μg
fluticasone
propionate
• 86% recution in s.c. group (p< 0.001, vs.
placebo)
• Improvement in FEV1 for both
groups (p< 0.05) and asthma scores
(p< 0.001)
Every 4 weeks for
32 weeks




• 100 mg s.c. every
4 weeks for
20 weeks
• Inclusion criteria did
not account
sputum eos
• Drug significantly reduced blood eos by
week 4 and was maintained throughout
study (p< 0.001)
• Median percentage decrease in OCS
from baseline - 50% in drug arm to
no reduction in placebo (p= 0.007)
Mepolizumab On 5–35 mg of daily
OCS, and severe
exacerbations
Phase III • Blood eos 150/μl at
screening or 300/μl
in previous year
• Relative reduction of 32% in annual
exacerbation rate despite lowering of
OCS in drug arm (p= 0.04, vs.
placebo)
• Improvement in ACQ-5 score
(p= 0.004)
Corren [30] 2014 Moderate-severe
asthma





• Abstract does not document any reduction
in blood eos
• Significant reduction in ACQ score in
drug arm (p= 0.04)
Reslizumab ACQ≥ 1.5 n= 97 (placebo)
On medium dose ICS
(~440 μg fluticasone)




blood eos≥ or ≤
400 cells /μl
• Only 20% of study population was
eosinophilic (or≤ 400 cells /μl)
• FEV1 improvement for overall
population by 68 ml, 270 ml for
eosinophilic patients (p= 0.04 vs.
placebo), ns increase of 33 ml in
non-eosinophilic patients
Bjermer [31] 2014 Eosinophilic asthma n= 311
db, pc, parallel
• 0.3 – 3.0 mg/kg, i.v.,
monthly (for 16 weeks)
• blood eos≥ 400
cells /μl
• eosinophil measurement was not
documented in the abstract
• overall improvement in FEV1
p ≤0.024, ACQ score (p ≤ 0.03)
Reslizumab ACQ≥ 1.5 • sputum eos not
accounted
Phase III • Higher dose - significant FEV1
increase as early as 4 weeks
Index: eos= eosinophils; db= double-blind; pc= placebo-controlled; mc= multi-center; sc= single-centre; FEV1= peak expiratory flow i.v= intravenous; s.c.= sub-cutaneous; wk= week; ns= non-significant; ACQ= Asthma
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also benefit from anti-IL5 therapy [35].
Using ‘sputum eosinophils’ as a biomarker to identify
IL5-treatment responsive patient-groups as well as a
marker for its therapeutic outcome is a topic under debate
[1]. Studies that considered patients with ≥ 2.5 - 3% spu-
tum eosinophilia in their inclusion criteria, independently
recorded significant improvements with asthma scores
and lung function [21,22] compared to others (see Table 1).
Similarly post hoc analysis showed that patients treated
with 1.0 mg/kg Reslizumab, with baseline sputum levels<
3% did not show improvement in the FEV1, (even with de-
pleted peripheral eosinophil levels) [18]. In fact, sputum
eosinophils do not correlate with a change in circulating
eosinophil numbers in the severe prednisone-dependent
asthmatic patients and the former is markedly reduced be-
fore an event of exacerbations [1].
Subcutaneous doses of Mepolizumab showed neither
significant reduction in sputum eosinophils (for 75 and
250 mg dosage groups) nor any relevant improvements
in the symptom scores or lung function (see Table 1,
[23]). The recent phase III trials documented depletion
of blood eosinophils, significant improvement in asthma
symptom scores and moderate reduction in exacerbation
rates with lower (100 mg) subcutaneous doses (refer to
Table 1), without any indication of whether the luminal
eosinophilia generally exhibited in the specific patient
group was resolved or not [28,29]. In contrast, 750 mg
intravenous infusions in the previous two studies of
similar disease profiles [21,22], were able to reduce both
circulating and sputum eosinophils, allow significant im-
provement in ACQ, FEV1 and quality of life score along
with pronounced reduction in exacerbations. This dis-
crepancy may reflect the therapeutic significance of the
drug delivery platform and dose used, a concern ad-
dressed in a recent editorial [32].
Further assessment of Anti-IL5 trials: molecular insights
The eosinophil biology is complex and outcomes from
the anti-IL-5 clinical trials reiterate this. Many of the
anti-IL-5 clinical trials (Table 1) document the presence
of tissue eosinophilia in spite of nil/low circulating
levels, post-treatment. Especially, both studies with Ben-
ralizumab showed 100% reduction of eosinophils in
bone-marrow and peripheral blood, but presence of air-
way mucosal/sub-mucosal eosinophils [26] and detect-
able levels of ECP in the sputum [25], indicating an
alternative mechanism to IL-5 for eosinophil initiation,
recruitment, activation and survival in the tissues. Delv-
ing further, Haldar et al., [22] showed significant de-
crease (P< 0.002) for both circulating blood and sputum
eosinophils (see Table 1) in the Mepolizumab study
group, which was not reflected in the paired bronchial-
biopsy specimens (obtained before and after the study).In context, antisense oligonucleotide therapy (TPI ASM8),
developed to suppress the expression of surface receptors
CCR3 (C-C chemokine receptor type 3, binds eotaxin)
and β chain (shared receptor for IL-5, IL-3 and granulo-
cyte macrophage-colony stimulating factor, GM-CSF)
[36], reduced sputum eosinophil counts by 46%; while a
CCR3 antagonist was recently documented to show no ef-
fect of blood or sputum eosinophilia or to have any clinic-
ally improvement in moderate to severe asthmatics [37].
Scattered evidences [2,11,38] instrument the presence of
alternative pathways in situ, that can trigger, activate and
maintain eosinophils in the sub-mucosal and mucosal sur-
faces, independent of the classical TH2 pathway activation
triggers (refer to Figure 1).
Extraneous environment-derived factors including non-
allergic sources like pathogens and epithelial damage can
trigger the release of epithelium-derived ‘Type-2 alarmins’ –
IL-25, IL-33, and thymic stromal lymphopoeitin (TSLP,
see Figure 1) [15,38]. IL-25 and IL-33 can initiate mast cell
(MC) response (mostly sub-mucosal localization) that
leads to the release of IL-5 and CCL5. In addition, the
type-2 alarmins activate the resident lineage negative, type
2, innate lymphoid cells (ILC2s) to release the classical
TH2 cytokines IL-5, IL-13, IL-9, that directly or indirectly
support eosinophil recruitment and survival in the tissues
(refer to Figure 1) [15,38-41]. Again, in vitro experiments
demonstrated TSLP in presence of pro-inflammatory
stimuli IL1-beta/tumor necrosis factor alpha (mimicking
an ongoing inflammatory state) activated MCs to release
IL-5 and IL-13; thereby, suggesting subsidiary mechanisms
that produce IL-5 and can promote eosinophil numbers in
the inflamed parenchyma/airway lumen [42]. IL-13 (and
IL-4 in airway smooth muscle, ASM) trigger the release of
eotaxins from the ASM [43] and the bronchial epithelium
[44] that promote recruitment of eosinophils and eosino-
phil progenitors (refer to Figure 1). Increased IL-13 and
IL-4 can promote the homing of CD34+ haemopoietic
progenitor cells into the airway parenchyma [45].
Evidence suggest that this mechanism maybe upstream
of activation by epithelial cell-derived cytokines [46,47].
Understanding physiological processes that promote air-
way eosinophilia in severe asthma may be critical to the
development of novel treatment modalities for optimal
asthma control. Luminal eosinophilia in asthma arise as
a result of (i) the recruitment of mature eosinophils from
the periphery in response to locally elaborated chemo-
attractants such as eotaxin and/or (ii) the localized matur-
ation of eosinophil lineage-committed progenitors, termed
“in situ differentiation” in the presence of locally elabo-
rated cytokines such as IL-5 [48,49]. That haemopoietic
progenitors differentiate within the tissue is inferred from
findings that there is increased recruitment of eosinophil
progenitor cells into the airways in asthmatics [50]. In
addition CD34+ cells extracted from human nasal polyp
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entiation to form mature eosinophils [51,52]. In context,
anti-IL5 mAbs reduce tissue and luminal eosinophils (see
Table 1), and are most effective in severe prednisone-
dependent asthmatics with eosinophilic bronchitis [21].
These findings suggest that local eosinophilopoiesis may
be a more dominant mechanism for the persistence of eo-
sinophils in the airways of patients with moderate-to-severe
asthma than chemokine-dependent (for e.g. eotaxin) re-
cruitment of mature eosinophils. Whilst this remains to be
determined, it may explain our recent findings where treat-
ment with anti-CCR3 failed to clear luminal eosinophils
likely because the treatment did not attenuate local differ-
entiative processes [37].
Controlling the development of airway eosinophilia may
involve targeting multiple factors that stimulate eosinophils
recruitment and modulate local differentiative processes or
prolonged tissue survival. A few conducted clinical trials
with mAbs targeting IL-4 and IL-13 biology, similar to
anti-IL-5, has met with a mixed response in improving
clinical symptoms [10]. However, a combination therapy
with drugs like Dupulimab (targets the receptor complex
common both IL-4 and IL-13) [53] and an anti-IL-5 mAb
could synergistically curb the mechanisms of in situ eosino-
philia plausibly altered in severe asthmatics, that render the
airways susceptible to maintain the clinical symptoms.
Anti-IL-5 therapy for other lung eosinophilic disorders
As evident from the on-going discussion, IL-5 and IL-5
receptor alpha (IL5Rα) exhibit an undeniable eosinophil
lineage-specificity. Indisputably, they have been consid-
ered as a potential therapeutic target in eosinophilic air-
way disorders.
Hypereosinophilic syndrome (HES)
HES is a heterogeneous rare disorder defined by the pres-
ence of >1500 eosinophils per μL of blood, persistent for ≥
6 months, with eosinophil-related organ involvement or
dysfunction and no identifiable secondary cause of eosino-
philia [5]. Early case studies with HES patients show con-
siderable improvement in disease symptoms, patient relief,
and decrease in eosinophilia with 750 mg intravenous
Mepolizumab [5]. Table 2 summarizes an open-label study
with 4 patients in 2004 [54] followed by a double-blinded,
multi-centered clinical trial with Mepolizumab in 2008,
where 41 out of 43 patients (on the experimental drug and
tapering strength of prednisone), managed to maintain a
circulating blood eosinophil count< 600/μL, for ≥8 weeks
(p< 0.0001, vs. placebo) [55]. Additionally, it could be an al-
ternative to using high-dose OCS, otherwise prescribed to
the patients diagnosed with T-lymphocyte variant of HES
[56]. A number of studies are currently underway to evalu-
ate other anti-IL5 molecules in addition to Mepolizumab
as potential therapeutic interventions in HES. A study withHES patients is projected to end in early 2017, which eval-
uates the safety and efficacy of Benralizumab (NCT02130
882) in these subjects (http://clinicaltrials.gov).
Eosinophilic Granulomatosis and Polyangitis (EGPA)
EGPA, earlier known as Churg-Strauss syndrome, is a rare
form of vasculitis characterized by asthma and eosino-
philia, with multi-organ involvement (lung, peripheral
nerves, heart, gastrointestinal tract, skin), where systemic
corticosteroid is the cornerstone of therapy [4,60]. Hist-
ology shows classic evidence of an eosinophilic inflamma-
tory response in the airway tissue of these patients and
hence Mepolizumab has been reasoned to be a potential
corticosteroid-sparing therapy. A recent case study re-
ported complete regression of asthma (discontinuation of
inhaled therapy) and depletion of blood and airway eosin-
ophils in a patient with refractory EGPA with monthly in-
fusions of 750 mg Mepolizumab [60]. Kim et al., 2010,
reported a significant (75%) reduction in circulating eosin-
ophils with 4 monthly doses of 750 mg (i.v) Mepolizumab,
in a small open label trial with 7 patients, that allowed safe
reduction of OCS from a mean dose of 18.8 mg to 4.6 mg
[57]. In addition, Mepolizumab at the same dosage allowed
complete remission in 8 out of 9 EGPA patients in a Phase
II uncontrolled trial (detailed in Table 1) [58]. Though
promising, further clinical investigations are necessary to
ascertain the therapeutic benefit of Mepolizumab in EGPA
and a large multicenter clinical trial is ongoing.
Chronic eosinophilic pneumonia (CEP)
Chronic eosinophilic pneumonia (CEP) is an idiopathic
condition that presents with peripheral eosinophilia, eo-
sinophilic infiltrates in the lung parenchyma and may
occasionally be associated with asthma. Increased levels
of IL-5 and release of cytotoxic granular proteins from
eosinophils constitutes an important pathomechanism in
pulmonary tissue damage observed in CEP [61]. Conven-
tionally OCS therapy is used for treatment; however, an
eosinophil-targeted therapy with Mepolizumab might re-
sult in steroid-sparing therapeutic benefit in CEP patients.
Chronic bronchitis (in COPD)
Chronic bronchitis is a primary component of COPD that
encompasses a high level of heterogeneity. A sputum
database analysis of 2443 patients with airway diseases, re-
vealed one-fifth of the COPD patients experience eosino-
philic bronchitis (EB). Additionally, EB was also associated
with the severity of airflow obstruction in non-asthmatic
COPD. 18% COPD patients with frequent exacerba-
tions were documented to have EB and associated eo-
sinophilia. Targeting eosinophils and IL-5 levels with
Mepolizumab may decrease exacerbation rates and im-
prove lung functions for this sub-set of COPD patients
[62], as documented for other eosinophil-driven airway




Disease (severity) Study design Dosage/ delivery Baseline eosinophil
count





3 doses 10 mg/kg or
750 mg (max) i.v.
every 4 wk
• Blood eos > 750/μL
after an 8 wk pre-
treatment run in
period
• Blood eos reduced in all patients,
sustained in 12 wk follow-up span
• Symptoms and quality of life improved in all
patients




db, pc,, mc, parallel
group study
750 mg i.v. at 4 wk
interval 36 wk study
• Blood eos<1000/μL
after a 6 week run-in
period with
prednisone therapy
• Blood eos<600/μl for 8 wks,
achieved in 95% patients in drug
group , 45% placebo, p< 0.0001
• Primary end-point (reduction of prednisone to
10 mg or less without clinical severity) was
reached 84% of patients in drug group, 43%
placebo, p< 0.0001Mepolizumab (patients negative for
FIP1L1-PDGFRA fusion
gene) Baseline (median all
patients):
• Blood eos (x 109/L):
0.447 ± 0.694






750 mg i.v. at 4 wk





daily dose of 20–
60 mg.
• Blood eos were maintained≤
600/μL by L-HES (Mepolizumab
group) for 8 wks and during the
entire length of the study
compared to placeb0
• Significant lower mean daily prednisone dose
of 4.64 mg in drug dosed group , compared to
28.3 mg in placebo (P=0.014)
Mepolizumab (T-lymphocytic variant) –
recruitment based on T-
cell phenotyping and
profile negative for FIP1L1-
PDGFRA gene
• Patients with low CCL17 levels were seen to
significantly maintain blood eos≤ 600 μl
Kim [57]/2010 EGPA n= 7 4 monthly 750 mg (i.v) • Mean eos count
3.4%
• Reduction in eos count from
2.9% (mean) to 0.4 at wk 16
(wash-out phase)
• Mean reduction in corticosteroid 18.8 mg to
4.6 mg, P< 0.001





• Eos mean 3.8% at wk 40 • Significant improvement of ACQ during study
and wash-out phase
• Patients clinically stable through study period,




Active refractory (n= 3) or




750 mg i.v. once
every 4 weeks (9
infusions in total)
• BVAS does not
include eos as a
criteria
• 6 patients (≥120 cells/μl) showed
reduction in eos from their
respective baseline, maintained
throughout.
• Disease extent dropped from 4at weel 0 to 0
at week 32 (p= 0.009)
Mepolizumab
OCS≥ 12.5 mg/daily • Variations in eos
levels ranged from 13
– 4282 cells/μl
• Eight patients achieved remission at week 32
(primary end-point), BVAS score= 0,
OCS<7.5 mg/dayBVAS≥ 3




















Table 2 Anti-IL5 trials in eosinophilic lung disorders (Continued)
Brightling [59]
2014
Moderate to severe n= 101 100 mg s.c. every
4 weeks (three
doses), then every




> 3% at screening or
past year
• Significant reduction in both
sputum and blood eosinophil
levels at week 4, and maintained
till week 56
• No changes in acute exacerbation rates, lung
function or symptom score between treatment
and placebo arm at week 56 for overall
populationBenralizumab COPD Phase II
Exacerbations≥ 1 in
previous year
Mc, pb,db • Sub-group analysis
stratified results based
on≥ 150 or≥ 200
or≥ 300 eosinophils/
μl
• Increase in blood and sputum
eos after final dose
• non-significant decrease in exacerbation rate
compared with placebo in patients with
baseline eosinophil counts of≥ 150 cells/ uL(p=
0°84), ≥ 200 cells/ uL (p= 0°26), or 300 cells/μl
(p= 0°28)
• Changes in FEV1 at week 56 was significant in
patients with blood eosinophil counts ≥150
cells/ μL (p= 0°031) or≥ 200 cells/ μL (p= 0°035),
and non-significant in those with counts of≥
300 cells/μL (p= 0°22)
Index: eos= eosinophils; db= double-blind; pc= placebo-controlled; mc=multi-center; sc= single-centre; FEV1= peak expiratory flow i.v.= intravenous; s.c.= sub-cutaneous; wk= week; ns= non-significant; FIP1L1–PDGFRA :




















Mukherjee et al. World Allergy Organization Journal 2014, 7:32 Page 12 of 14
http://www.waojournal.org/content/7/1/32disorders (discussed previously). However, as per the
recent reports of Brightling and co-workers, no reduc-
tion in annual exacerbation rates was observed in mod-
erate to severe COPD patients with eosinophilia (>3%
sputum eosinophils) when treated with a monthly/bi-
monthly subcutaneous dose of 100 mg Benralizumab,
even though the treatment effectively depleted both air-
way and circulating eosinophils (refer to Table 2) [59].
Nevertheless, online database (http://clinicaltrials.gov,
last accessed 16/09/2014) enlists ongoing independent
studies investigating efficacy and safety of Mepolizumab
as an adjunct treatment in COPD management (regis-
tration number: NCT02105961); in COPD with EB (NC
T01463644); reducing exacerbations in severe COPD
(NCT02105948); and Phase III trials for Benralizumab
in moderate to very severe COPD (NCT02155660, NC
T02138916), addressing safety and efficacy of the drug.Summary
The ongoing anti-IL5 clinical trials, show promise of a
safe, effective treatment option for the severe ‘eosino-
philic’ asthma endotype independent of their atopic sta-
tus [63]. Beyond asthma, small pilot studies have
documented their potential in treating HES and EGPA
patients. IL-5 may not be the sole determinants of per-
sistent airway eosinophilia. Recently described immune
cells such as the ILC2s and epithelium-derived type-2
alarmins that release TH2 cytokines like IL-13 may also
play important rolesHence, targeting IL-5 and IL-13 to
curb the eosinophil-derived clinical symptoms needs to
be investigated in select patient-subtypes. Finally, while
blood eosinophil count or other indirect assessments
such as the eosinophil/lymphocyte ratios may help to
identify an “eosinophilic phenotype” to initiate therapy
with an anti-eosinophil biologic drug in patients with
moderate asthma, this strategy may not be as effective as
measuring sputum eosinophils to monitor response to
therapy particularly in more severe systemic corticosteroid-
dependent asthmatic patients. The key to successful ther-
apy would be to select the appropriate patient population.
The mere presence of eosinophils in blood or sputum may
not be sufficient. The patients who are likely to respond are
those whose disease is truly largely dependent on eosino-
phil biology. Identification of these patients require clinical
acumen, clinical criteria and demonstration of persistent
(not transient) systemic and airway eosinophilia.Abbreviations
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